Teal Health key facts
as of Oct 2026- Developer of at-home cervical cancer screening devices designed to provide a convenient and private alternative to traditional clinical screenings.
- Teal Health is valued at approximately $107.0M as of Oct 2026, set at its Series A, Aug 2026; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $23.4M across 2 recorded rounds; the latest was Series A ($22.0M) in Aug 2026.
- Notable investors include MedTech Innovator, Felicis, Tribe Capital, Precursor Ventures, Forerunner Ventures — 20 tracked in total.
- Teal Health has filed 1 Form D with the SEC, most recently Jan 2025 ($23.5M sold to 74 investors).
- Status: Privately Held (backing).
Valued at $107.0M at its Series A, Aug 2026. Nothing has traded since.
- ·The post-money valuation on its round
- ·The complete investor list: 20 names
- ·Watch Teal Health: the Monday email on marks, rounds and moves
Teal Health funding rounds
2 roundsWho backs Teal Health
20+Teal Health valuation
Teal Health was valued at $107 million at its Series A in Aug 2026. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
Recent activity
In the last 90 days, Teal Health's record added 1 funding round.
How much has Teal Health raised?
Teal Health has raised $23.4 million across 2 recorded rounds since 2024. The largest was a $23.5 million early-stage round in Nov 2024; the most recent was a $22 million Series A in Aug 2026. 1 of the rounds disclosed a post-money valuation.
Teal Health has filed 1 Form D with the SEC, most recently in Jan 2025 ($23.5 million sold to 74 investors).
Teal Health investors
20 investors are on record for Teal Health, including MedTech Innovator, Felicis, Tribe Capital and Precursor Ventures. By type, the record holds 6 venture capital firms. The Series A in Aug 2026 drew 7 investors.
About Teal Health
Developer of at-home cervical cancer screening devices designed to provide a convenient and private alternative to traditional clinical screenings. The company offers a platform that includes an FDA-approved sampling device, virtual consultations with licensed providers, secure laboratory testing using the same primary human papillomavirus (HPV) test as clinical settings, an online portal for viewing results, and coordination of follow-up care, enabling women and healthcare providers to increase screening accessibility, improve early detection rates, and reduce barriers associated.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2018
- Employees
- 21
- Website
- getteal.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.